1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

Summary

Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, being responsible for approximately 90% of all cases in adults. The condition is asymptomatic in its initial stages, and as a result, people with RCC are often in the advanced stages of the disease by the time it is discovered. The initial symptoms of RCC often include blood in the urine, flank pain, a mass in the abdomen or flank, weight loss, fever, hypertension, night sweats, and a general feeling of being unwell. Kidney cancer is among the 10 most frequently occurring cancers in Western countries. Globally, about 270,000 cases of kidney cancer are diagnosed yearly, and 116,000 people die from the disease.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of RCC in the 8MM, from 190,147 diagnosed incident cases in 2013 to 309,734 diagnosed incident cases in 2023, with an Annual Growth Rate (AGR) of 6.29% during the forecast period. In 2023, urban China will have the highest number of diagnosed incident cases of RCC in the 8MM, with 147,457 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of RCC, with 7,591 diagnosed incident cases. Similarly, as shown in the second figure below, the five-year diagnosed prevalent cases of RCC in the 8MM will increase from 600,261 diagnosed prevalent cases in 2013 to 966,190 diagnosed prevalent cases in 2023, with an AGR of 6.10% during the forecast period. The increase in the diagnosed five-year prevalent cases of RCC is partly attributed to the rising trend in the incidence rate of RCC in the 8MM, combined with changes in the population demographics in the respective markets.The rising trend in the incidence of RCC may partly be a result of increased use of imaging techniques that can detect asymptomatic tumors.

Scope

- The Renal cell carcinoma (RCC) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for RCC in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of RCC, segmented by age (at 20-year intervals, starting at age 20 years and ending at ages =80 years) and sex. It also includes a forecast of the five-year diagnosed prevalent cases of RCC in the 8MM. Additionally, it provides the RCC diagnosed incident cases, segmented by the stage at diagnosis, for the 8MM.
- The RCC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The RCC EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global RCC market.
- Quantify patient populations in the global RCC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RCC therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Upcoming Related Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 12
3.3.1 Incidence 12
3.3.2 Survival Rates for RCC - 8MM 14
3.4 Forecast Methodology 15
3.4.1 Sources Used 17
3.4.2 Sources Not Used 20
3.4.3 Forecast Assumptions and Methods, RCC Diagnosed Incident Cases 21
3.4.4 Forecast Assumptions and Methods, RCC Five-Year Diagnosed Prevalent Cases 21
3.4.5 Forecast Assumptions and Methods, RCC Clinical Stages at Diagnosis 22
3.5 Epidemiological Forecast for RCC (2013-2023) 23
3.5.1 Diagnosed Incident Cases of RCC 23
3.5.2 Age-Specific Diagnosed Incident Cases of RCC 25
3.5.3 Sex-Specific Diagnosed Incident Cases of RCC 27
3.5.4 Age-Standardized Diagnosed Incidence of RCC 29
3.5.5 Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis 31
3.5.6 Five-Year Diagnosed Prevalent Cases of RCC 32
3.6 Discussion 33
3.6.1 Epidemiological Forecast Insight 33
3.6.2 Limitations of the Analysis 34
3.6.3 Strengths of the Analysis 34
4 Appendix 36
4.1 Bibliography 36
4.2 About the Authors 39
4.2.1 Epidemiologists 39
4.2.2 Reviewers 39
4.2.3 Global Director of Therapy Analysis and Epidemiology 40
4.2.4 Global Head of Healthcare 40
4.3 About GlobalData 41
4.4 About EpiCast 41
4.5 Disclaimer 42

1.1 List of Tables
Table 1: RCC Clinical Stages at Diagnosis 10
Table 2: Risk Factors and Comorbidities for RCC 11
Table 3: Trends in the Age-Adjusted Incidence of Kidney Cancers in the US, Ages ?20 Years, 1993-2007 12
Table 4: Trends in the Age-Adjusted Incidence of Kidney Cancers in the 5EU, Ages ?20 Years, 1993-2007 13
Table 5: Trends in the Age-Adjusted Incidence of Kidney Cancers in Japan, Ages ?20 Years, 1993-2007 13
Table 6: Trends in the Age-Adjusted Incidence of Kidney Cancers in Urban China, Ages ?20 Years, 1993-2007 14
Table 7: Trends in the Five-Year Relative Survival (%) of Kidney Cancers in the 8MM, Both Sexes, 1993-2009 15
Table 8: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Incident Cases 16
Table 9: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Five-Year Prevalent Cases 16
Table 10: 8MM, Sources of Epidemiological Data Used for the Segmentation of RCC Incident Cases by Clinical Stage at Diagnosis 17
Table 11: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ?20 Years, N, 2013-2023 24
Table 12: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N (Row %), 2013 26
Table 13: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ?20 Years, N (Row %), 2013 28
Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ?20 Years, N, 2013-2023 32

1.2 List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ?20 Years, N, 2013-2023 24
Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2013 27
Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ?20 Years, N, 2013 29
Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RCC (Cases per 100,000 Population), Ages ?20 Years, by Sex, 2013 30
Figure 5: 8MM, Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis, Ages ?20 Years, N, 2013 31
Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ?20 Years, N, 2013-2023 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Renal Cancer: Analytical Tool

Renal Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Renal cell carcinoma- Market Insights, Epidemiology and Market Forecast-2023

Renal cell carcinoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Renal cell carcinoma - Epidemiology Forecast To 2023

Renal cell carcinoma - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Renal cell carcinoma - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Renal cell carcinoma in seven major markets (US, France, Germany, Italy, Spain, ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.